Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ana-Maria Vranceanu, Ph.D.


This page shows the publications co-authored by Ana-Maria Vranceanu and Vanessa Merker.
Connection Strength

  1. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
    View in: PubMed
    Score: 0.761
  2. Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey. Am J Med Genet A. 2021 Sep 18.
    View in: PubMed
    Score: 0.249
  3. First report of factors associated with satisfaction in patients with neurofibromatosis. . 2017 03; 173(3):671-677.
    View in: PubMed
    Score: 0.181
  4. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
    View in: PubMed
    Score: 0.178
  5. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
    View in: PubMed
    Score: 0.174
  6. Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
    View in: PubMed
    Score: 0.172
  7. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
    View in: PubMed
    Score: 0.157
  8. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
    View in: PubMed
    Score: 0.151
  9. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
    View in: PubMed
    Score: 0.141
  10. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S50-S63.
    View in: PubMed
    Score: 0.061
  11. Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.